v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash $ 5,960,594 $ 5,069,266
Advances on research and development contract services 216,018 76,898
Prepaid insurance 98,323 67,311
Other prepaid expenses and current assets 32,224 15,000
Total current assets 6,307,159 5,228,475
Deferred offering costs 26,376
Total assets 6,333,535 5,228,475
Current liabilities:    
Accounts payable and accrued expenses, including $60,333 and $0 to related parties at September 30, 2021 and December 31, 2020, respectively 232,016 190,292
Accrued offering costs 10,467
Research and development contract liabilities 26,683 15,765
Total current liabilities 258,699 216,524
Commitments and contingencies  
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 729,167 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 13,746,593 shares and 12,402,157 shares at September 30, 2021 and December 31, 2020, respectively 1,374 1,240
Additional paid-in capital 37,626,264 31,864,479
Accumulated deficit (35,052,802) (30,353,768)
Total stockholders’ equity 6,074,836 5,011,951
Total liabilities and stockholders’ equity $ 6,333,535 $ 5,228,475

Source